Alteon's alagebrium could possibly reverse diabetic kidney disease

By Lisa Kerner

Charlotte, N.C., Sept. 20 - Alteon Inc. said results of a preclinical study of alagebrium, a novel advanced glycosylation end-product breaker, expands existing evidence of the potential ability of alagebrium to reverse diabetic kidney disease.

In addition, the study also identifies a role for biomarkers to track drug effectiveness in anticipated clinical trials of alagebrium for diabetic nephropathy and diastolic heart failure.

The Parsippany, N.J., biopharmaceutical company's study evaluated the effects of alagebrium on 3, 7 and 12 month old db/db mice, which represent a model of human diabetes.

Alteon's results are published in the current issue of the American Journal of Nephrology.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.